Panagora Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Panagora Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-53,136	Closed	-$43K	–	2610
2020 Q1	$43K	Sell	53,136 -30,308	-36%	-$30.2K	﹤0.01%	1924
2019 Q4	$69K	Sell	83,444 -184,844	-69%	-$154K	﹤0.01%	1871
2019 Q3	$262K	Sell	268,288 -66,626	-20%	-$69K	﹤0.01%	1534
2019 Q2	$368K	Buy	+334,914	New	+$386K	﹤0.01%	1549
2017 Q3	–	Sell	-3,695	Closed	-$10K	–	2416
2017 Q2	$10K	Buy	+3,695	New	+$10.3K	﹤0.01%	2405
2015 Q2	–	Sell	-21,824	Closed	-$88K	–	2450
2015 Q1	$88K	Buy	+21,824	New	+$75.5K	﹤0.01%	1969

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Panagora Asset Management's LCTX Position: Q2 2020 in Review

Panagora Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2020, closing a stake of 53,136 shares — an estimated $43K sold.

Panagora Asset Management first reported a position in LCTX in Q1 2015 and held it in 6 quarters. The position peaked at $368K in Q2 2019. 94 funds tracked by Wall St. Rank hold LCTX as of Q2 2020.

Panagora Asset Management reported no remaining Lineage Cell Therapeutics position as of Q2 2020 after selling out during the quarter.
Panagora Asset Management sold 53,136 Lineage Cell Therapeutics shares in Q2 2020, an estimated $43K.
Panagora Asset Management first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 6 quarters.
Panagora Asset Management's Lineage Cell Therapeutics position peaked at $368K in Q2 2019.
94 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2020.

Based on Panagora Asset Management's 13F filing for Q2 2020, filed 12 Aug 2020.